Oxyphenbutazone ameliorates carfilzomib induced cardiotoxicity in rats via inhibition of oxidative free radical burst and NF-κB/IκB-α pathway.
Cardiotoxicity
Carfilzomib
Chemotherapy
Inflammation
Oxyphenbutazone
Journal
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
ISSN: 1319-0164
Titre abrégé: Saudi Pharm J
Pays: Saudi Arabia
ID NLM: 9705695
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
05
11
2023
accepted:
16
12
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
16
1
2024
Statut:
ppublish
Résumé
Carfilzomib (CFZ), a chemotherapeutic agent used for multiple myeloma treatments reported to cause high incidence of cardiac events either new onset and/or exacerbate formerly diagnosed heart failure with ventricular and myocardial dysfunction.
Identifiants
pubmed: 38226350
doi: 10.1016/j.jsps.2023.101926
pii: S1319-0164(23)00421-8
pmc: PMC10788627
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101926Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.